Company Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction.
Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity.
The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
| Country | n/a |
| IPO Date | Mar 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Jodie Pope Morrison |
Contact Details
Address: No Address available No city data available, | |
| Website | n/a |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US7469641051 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer & Director |
| Dr. Saul Fink Ph.D. | Chief Technology Officer |
| Lee H. Kalowski M.B.A. | Chief Financial Officer & President |
| David Appugliese J.D. | Senior Vice President & Head of People |
| Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer & President of Research |
| Kathryn E. Golden M.B.A. | Head of Chemistry, Manufacturing & Controls |
| Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy & Program Operations |